Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$14.50B |
$77.53
-0.06%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$14.25B |
$20.79
-0.41%
|
|
FMS
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care manufactures and provides Blood Purification Devices used in dialysis, including the 5008X CAREsystem.
|
$13.98B |
$23.91
+0.36%
|
|
BBIO
BridgeBio Pharma, Inc.
Attruby (acoramidis) and other BridgeBio pipeline assets are oral small-molecule therapeutics, covering multiple rare genetic diseases.
|
$13.71B |
$71.36
-0.51%
|
|
NDSN
Nordson Corporation
Atrion's medical components and medical device technologies place Nordson in the medical devices & biometrics space.
|
$13.45B |
$237.97
-0.01%
|
|
GH
Guardant Health, Inc.
Core product category: Guardant Health's liquid biopsy tests (Guardant360 Liquid/Tissue) are the primary offerings.
|
$13.44B |
$107.61
-0.16%
|
|
TEM
Tempus AI, Inc.
Laboratory Testing & Advisory Services – Tempus provides outsourced laboratory testing and regulatory/advisory support.
|
$13.41B |
$76.90
-0.40%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$13.40B |
$597.13
-0.65%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$13.24B |
$17.93
+0.62%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$13.18B |
$82.18
-0.63%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$13.10B |
$90.78
+2.33%
|
|
UNM
Unum Group
Health Insurance products are part of Unum's workplace benefits and risk protections in the employee benefits mix.
|
$13.01B |
$76.47
+0.12%
|
|
DOC
Healthpeak Properties, Inc.
The CCRCs and healthcare facilities component places Healthpeak in Healthcare Services & Facilities.
|
$12.66B |
$18.25
+0.19%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$12.40B |
$10.62
-0.14%
|
|
GMED
Globus Medical, Inc.
Orthopedic devices and implants (spinal, ALIF spacers, knee systems) sold for reconstruction.
|
$12.30B |
$90.84
-0.26%
|
|
RVTY
Revvity, Inc.
Revvity's Diagnostics segment includes diagnostic equipment and instruments.
|
$12.15B |
$104.72
+0.05%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$12.08B |
$212.57
+1.22%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.90B |
$44.60
+0.89%
|
|
EHC
Encompass Health Corporation
Encompass Health operates inpatient rehabilitation hospital services, aligning with the Hospital Services investable theme.
|
$11.71B |
$115.84
-0.35%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.67B |
$13.97
-0.14%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.58B |
$23.29
-0.11%
|
|
PEN
Penumbra, Inc.
Penumbra's core offerings include vascular intervention devices used for thrombectomy and catheter-based clot removal.
|
$11.54B |
$295.33
-0.21%
|
|
GL
Globe Life Inc.
Supplemental health/health insurance products marketed by Globe Life.
|
$10.92B |
$135.14
+0.20%
|
|
ENSG
The Ensign Group, Inc.
ENSG's core business is providing post-acute healthcare services and facilities management (skilled nursing, rehabilitative services, senior living) across facilities.
|
$10.79B |
$186.68
-0.15%
|
|
QGEN
Qiagen N.V.
QIAGEN directly manufactures diagnostic instruments (e.g., QIAstat-Dx, QIAcuity, QIAsymphony Connect) and automated platforms.
|
$10.77B |
$47.79
-0.64%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.73B |
$176.03
-0.50%
|
|
ALGN
Align Technology, Inc.
Align's Invisalign system, iTero scanners, and direct 3D-printed dental devices are core dental equipment products.
|
$10.67B |
$147.10
-0.08%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.66B |
$55.26
-0.47%
|
|
WBA
Walgreens Boots Alliance, Inc.
Home Health & Hospice – Through CareCentrix and related services, Walgreens provides home health coordination and related care services.
|
$10.36B |
$11.98
|
Showing page 5 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
